Buy CAPR by Oct 22, 2026.

Capricor Therapeutics, one of the most controversial Biotech stocks of the past 12 months is nearing their imminent approval, in the face of many short sellers pushing retail short interest of float above 200%, once again, this time with already released positive clinical data. Upcoming Dates: 7/29 - ADCOMM - Public link with YouTube access 8/22 - Targeted PDUFA Date September - Expected Outcome of OSC from Nippon Distribution New Headquarters & Production facility for integrated productions and drug rollout. …